GLP-1 Side Effects: The Real Rates, and Which Ones Actually Matter

Almost every man starting a GLP-1 has been told there are “some stomach side effects.” That framing is doing a lot of work. The real rates are on the label, they are much higher than most people expect, and the useful skill is telling the difference between the effects that are unpleasant-but-expected and the two or three that mean stop and pick up the phone.

What are the real GLP-1 side effect rates?

These are the adverse reactions reported in at least 5% of adults in the semaglutide trials, straight from the prescribing information.

Read that first row again. Nearly half of people taking this drug feel sick at some point. That is not a rare reaction or a sign something has gone wrong. It is the modal experience, and being told to expect it changes how people cope with it enormously.

The second thing worth knowing is that these numbers describe any occurrence over the whole trial, not a permanent state. Most gastrointestinal effects are mild to moderate, cluster around the weeks when the dose goes up, and fade as the body adapts at a given dose.

How many people actually quit over it is the more decision-relevant number. In the head-to-head trial, gastrointestinal side effects caused 5.6% of people on semaglutide and 2.7% of those on tirzepatide to stop treatment. So: very common to feel it, uncommon to abandon the drug because of it.

Why does going up in dose too fast cause problems?

GLP-1 dosing starts low and steps up over months, and the reason is entirely about tolerability rather than efficacy. Every step up is a fresh opportunity for nausea.

Which gives you a lever most people do not realise they have. If a dose increase is intolerable, staying at the previous dose for longer, rather than pushing through or quitting: is a legitimate and commonly used strategy. A slower climb to the same destination generally beats a fast climb you abandon at month three.

The practical measures that help are dull and they work: smaller meals, stopping at the first sign of fullness rather than at the plate being empty, less fat and less fried food on injection days, and not lying down straight after eating. Constipation responds to fluid and fibre in the ordinary way.

Which side effects mean you should stop?

Set apart from the common effects, a short list warrants immediate contact with a clinician rather than management at home.

• Severe, persistent abdominal pain, particularly pain radiating to the back, with or without vomiting — the presentation of pancreatitis.
• Pain in the upper right abdomen, fever, or yellowing of the eyes or skin: gallbladder disease, which is more common during rapid weight loss generally and is listed as a warning for these drugs specifically.
• Sudden loss of vision or rapidly worsening eyesight: see below.
• Persistent vomiting that stops you keeping fluids down, which becomes a dehydration and kidney problem quickly.
• A lump in the neck, hoarseness, or trouble swallowing — the symptoms the thyroid warning exists for.

None of these is common. All of them are worth recognising, because the failure mode is assuming that severe symptoms are just a stronger version of the expected ones.

How worried should you be about the thyroid warning?

Semaglutide carries a boxed warning, the FDA’s most serious category, stating that in rodents it causes thyroid C-cell tumours at clinically relevant exposures, and that it is unknown whether it causes such tumours, including medullary thyroid carcinoma, in humans.

That wording deserves reading carefully, because it is doing two things at once. It is a real warning based on real animal data. It is also explicitly an open question in humans rather than a demonstrated human risk.

What follows from it is concrete: the drug is contraindicated if you have a personal or family history of medullary thyroid carcinoma, or of multiple endocrine neoplasia syndrome type 2. That is a question you should be asked before a prescription is written, and one worth raising yourself if nobody does.

What is the eye risk with semaglutide?

This one is new enough that many prescribers have not caught up with it.

Through 2025, regulators examined a possible link between semaglutide and non-arteritic anterior ischaemic optic neuropathy, NAION, a sudden loss of blood supply to the optic nerve that causes painless vision loss, usually in one eye, usually permanent.

The European Medicines Agency classified it as a very rare side effect, meaning it may affect up to 1 in 10,000 users, and required it be added to the product information for semaglutide medicines. In June 2025 the World Health Organization’s safety committee agreed it belonged in the drug’s risk management plan.

Very rare is genuinely very rare, and it is not a reason for most people to avoid the drug. It is a reason to know one sentence: if your vision suddenly drops or deteriorates rapidly, contact a doctor immediately, and if NAION is confirmed the drug is stopped.

What does the label not tell you?

Two consequences of these drugs sit outside the adverse-events table because they are not adverse events in the regulatory sense.

The first is lean tissue. A meaningful share of the weight lost is muscle rather than fat, roughly proportionate to any large weight loss, but real, and it does not come back on its own. The body composition data and the mitigation are covered separately.

The second is what happens when you stop, which is the single most under-communicated fact in this category. Roughly two-thirds of the loss returns within a year.

How do you manage the side effects?

Expect to feel sick. Nearly half of people do, and knowing that in advance is most of the coping strategy.

Treat every dose increase as the moment to watch, and treat holding at a lower dose as a legitimate option rather than a failure.

Learn the five stop-and-call symptoms above, and make sure someone asked you about thyroid cancer in the family before you started.

And do not source the drug outside the regulated supply chain. Dosing errors are a substantial share of the harm reported with compounded versions, and the side-effect profile above assumes you are getting the dose you think you are.

This article is for information only and is not medical advice. It cannot account for your individual circumstances. Talk to a doctor about your own situation, particularly before starting or stopping any prescription medication.